An issue of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) debt fell 4.8% against its face value during trading on Thursday. The high-yield debt issue has a 6% coupon and is set to mature on July 15, 2023. The bonds in the issue are now trading at $72.25 and were trading at $79.25 one week ago. Price moves in a company’s debt in credit markets sometimes predict parallel moves in its stock price.
A number of brokerages recently commented on ENDP. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Endo International PLC in a report on Sunday, July 23rd. Royal Bank of Canada set a $15.00 price objective on Endo International PLC and gave the company a “hold” rating in a research report on Sunday, July 16th. BidaskClub upgraded Endo International PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Zacks Investment Research downgraded shares of Endo International PLC from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Finally, Cantor Fitzgerald set a $9.00 price target on shares of Endo International PLC and gave the company a “hold” rating in a research note on Tuesday, August 8th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have given a buy rating to the company’s stock. Endo International PLC presently has an average rating of “Hold” and an average price target of $11.67.
Shares of Endo International PLC (NASDAQ ENDP) traded up $0.84 on Friday, hitting $6.93. 12,136,900 shares of the stock were exchanged, compared to its average volume of 7,342,927. The stock has a market capitalization of $1,359.98, a price-to-earnings ratio of 1.26 and a beta of 0.53. The company has a quick ratio of 0.80, a current ratio of 1.02 and a debt-to-equity ratio of 10.20. Endo International PLC has a 12-month low of $5.77 and a 12-month high of $18.63.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last posted its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. The company had revenue of $786.90 million during the quarter, compared to the consensus estimate of $794.93 million. Endo International PLC had a negative net margin of 126.97% and a positive return on equity of 56.97%. The firm’s quarterly revenue was down 11.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.01 earnings per share. equities research analysts forecast that Endo International PLC will post 3.54 EPS for the current fiscal year.
In other Endo International PLC news, CFO Blaise Coleman bought 6,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The stock was bought at an average cost of $7.89 per share, for a total transaction of $51,285.00. Following the completion of the transaction, the chief financial officer now directly owns 13,729 shares of the company’s stock, valued at approximately $108,321.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have purchased 16,000 shares of company stock valued at $125,460 over the last 90 days. 0.50% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. LMR Partners LLP acquired a new position in Endo International PLC during the third quarter valued at $148,000. Van ECK Associates Corp lifted its position in Endo International PLC by 67.1% during the third quarter. Van ECK Associates Corp now owns 340,991 shares of the company’s stock valued at $2,921,000 after purchasing an additional 136,873 shares during the period. Alps Advisors Inc. raised its position in shares of Endo International PLC by 9.3% in the third quarter. Alps Advisors Inc. now owns 250,511 shares of the company’s stock worth $2,146,000 after acquiring an additional 21,373 shares during the period. Gamco Investors INC. ET AL raised its position in shares of Endo International PLC by 76.2% in the third quarter. Gamco Investors INC. ET AL now owns 110,500 shares of the company’s stock worth $946,000 after acquiring an additional 47,800 shares during the period. Finally, Crossmark Global Holdings Inc. acquired a new position in shares of Endo International PLC in the third quarter worth about $293,000. Institutional investors own 90.32% of the company’s stock.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.